Zanubrutinib versus bendamustine and rituximab in untreated patients with CLL/SLL Zanubrutinib versus bendamustine and rituximab in untreated patients with CLL/SLL February 2025 Clinical trials Read more
2022 March Pharma News FDA approval for ciltacabtagene autoleucel for Relapsed/Refractory Multiple Myeloma Read more
2022 March Science Survival benefits with bortezomib in children with T-cell lymphoblastic leukaemia Read more
2022 March Science UBTF tandem duplication is a recurrent high-risk mutation in pediatric AML Read more
2022 March Prevention A new drug target to overcome obesity-induced chemoresistance in B-acute lymphoblastic leukaem... Read more
2022 March Pharma News FDA: major safety concerns with Ukoniq, PI3K inhibitor drug for treatment of lymphoma Read more
2022 March Clinical trials Consistent benefits of brentuximab vedotin plus chemotherapy for CD30-positive peripheral T-ce... Read more
Top
